Please login to the form below

Not currently logged in
Email:
Password:

neutropaenia

This page shows the latest neutropaenia news and features for those working in and with pharma, biotech and healthcare.

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia. Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. ... Lonquex (lipegfilgrastim) has been approved to reduce the

Latest news

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Teva's current efforts in the area include tbo-filgrastim - a biosimilar version of Amgen's Neupogen, which is approved for use  to hasten recovery from instances of neutropaenia in certain

  • R&D news in brief

    ìThe drug appears to be well tolerated, with thrombocytopaenia and neutropaenia, being the main side effects that require careful monitoring.î.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics